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Abstract
Background: The package leaflet included in the packaging of all medicinal products plays an important role in the transmission
of medicine-related information to patients. Therefore, in 2009, the European Commission published readability guidelines to
try to ensure that the information contained in the package leaflet is understood by patients.
Objective: The main objective of this study was to calculate and compare the readability levels and length (number of words)
of the package leaflets for biological medicines in 2007, 2010, and 2013.
Methods: The sample of this study included 36 biological medicine package leaflets that were downloaded from the European
Medicines Agency website in three different years: 2007, 2010, and 2013. The readability of the selected package leaflets was
obtained using the following readability formulas: SMOG grade, Flesch-Kincaid grade level, and Szigriszt’s perspicuity index.
The length (number of words) of the package leaflets was also measured. Afterwards, the relationship between these quantitative
variables (three readability indexes and length) and categorical (or qualitative) variables were analyzed. The categorical variables
were the year when the package leaflet was downloaded, the package leaflet section, type of medicine, year of authorization of
biological medicine, and marketing authorization holder.
Results: The readability values of all the package leaflets exceeded the sixth-grade reading level, which is the recommended
value for health-related written materials. No statistically significant differences were found between the three years of study in
the readability indexes, although differences were observed in the case of the length (P=.002), which increased over the study
period. When the relationship between readability indexes and length and the other variables was analyzed, statistically significant
differences were found between package leaflet sections (P<.001) and between the groups of medicine only with regard to the
length over the three studied years (P=.002 in 2007, P=.007 in 2010, P=.009 in 2013). Linear correlation was observed between
the readability indexes (SMOG grade and Flesch-Kincaid grade level: r2=.92; SMOG grade and Szigriszt’s perspicuity index:
r2=.81; Flesch-Kincaid grade level and Szigriszt’s perspicuity index: r2=.95), but not between the readability indexes and the
length (length and SMOG grade: r2=.05; length and Flesch-Kincaid grade level: r2=.03; length and Szigriszt’s perspicuity index:
r2=.02).
Conclusions: There was no improvement in the readability of the package leaflets studied between 2007 and 2013 despite the
European Commission’s 2009 guideline on the readability of package leaflets. The results obtained from the different readability
formulas coincided from a qualitative point of view. Efforts to improve the readability of package leaflets for biological medicines
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are required to promote the understandability and accessibility of this online health information by patients and thereby contribute
to the appropriate use of medicines and medicine safety.
(J Med Internet Res 2016;18(5):e100)   doi:10.2196/jmir.5145
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Introduction
Today, health care professionals are no longer the only source
of information for patients on matters related to health because
the new information and communication technologies have
increased the capacity of patients to seek information
independently [1-3]. That is why patient education is growing
in importance; in particular, written health-related materials
available on the Internet [4], such as package leaflets provided
by manufacturers.
One aspect that influences understanding of written information
is literacy, which is defined as “using printed and written
information to function in society, to achieve one’s goals, and
to develop one’s knowledge and potential” [5]. On the basis of
this concept, health literacy is defined as “the degree to which
individuals have the capacity to obtain, process, and understand
basic health information and services needed to make
appropriate health decisions” [6]. The capacity of the individual
is an important aspect in the definition of health literacy,
referring to both innate and acquired skills [7].
Health literacy plays an important role in the evaluation of the
online health information [8]. An improvement in health literacy
leads to a greater ability of patients to understand how to use
medicines appropriately and that is why adequate levels of health
literacy can improve medication safety and reduce adverse drug
reactions [9,10].
Another aspect that also influences the understanding of written
information is its readability, which can be measured using
readability formulas. By the 1980s, there were some 200
published readability formulas and a large number of studies
that attested to their validity [11]. Nowadays, these formulas
are widely applied to measure the readability of health-related
written materials [12-15]. It is recommended that the readability
level of health-related written materials for end users is not
higher than the sixth (age 11-12 years) [7,16] or seventh (age
12-13 years) grade [17].
Among health-related written materials, the package leaflet is
“a leaflet containing information for the user which accompanies
the medicinal product” [18]. It is very important for the
transmission of drug-related information to citizens and it can
help to supplement and reinforce the information received from
health professionals [19], possibly leading to increased
adherence and a consequent decrease in health care costs [4,20].
Several studies have highlighted problems associated with the
quality of the information contained in the European model of
the package leaflet [21,22]. This is in contrast with current
European regulations, according to which the contents of the
package leaflet must be clear and understandable, enabling the
users to act appropriately, and it must be clearly legible in the
official language or languages of the Member State [23]. To
achieve this aim, and in accordance with Article 65(c) of
Directive 2001/83/EC, in 2009, the European Commission
published the Guideline on the Readability of the Labelling and
Package Leaflet of Medicinal Products for Human Use, which
offers guidance on the writing of the labeling and package leaflet
to facilitate understanding and the accessibility of their content
[24]. The guidance recommends, among other things, the use
of simple words with few syllables and avoidance of long
sentences. These explicitly refer to variables included in
readability formulas (word length and sentence length).
The European Commission has final authority for authorizing
the commercialization of human medicines within the European
Union via a centralized authorization procedure. This centralized
procedure is compulsory for biological medicines, among others
[25]. In 1982, an insulin product became the first recombinant
medicine approved for sale [26]. Since then, many biological
medicines have been authorized for the treatment of a wide
variety of diseases. The biological product market is projected
to grow over the coming years and that may affect the
introduction both of new products and of existing products for
additional indications [27]. In January 2013, there were 171
biological medicines authorized in the European Union [28],
12 of which were biosimilars [29].
In a previous study, the readability levels of package leaflets of
some biological medicines (n=33) downloaded from the
European Medicines Agency (EMA) website was studied
between 2007 and 2010. No variation in readability was found
between the two years—the readability of the package leaflets
was above the recommended values for health-related
materials—and there were differences between the readability
levels of the different sections of package leaflets [30]. In view
of these findings, it seems important to extend the study to 2013
to see whether the guidance on readability has had an effect in
package leaflets until that date.
Thus, the main objective of the current study was to calculate
and compare the readability level and length (number of words)
of the package leaflets of biological medicines in 2007, 2010,
and 2013. We hypothesize that there will be an improvement
in the readability of package leaflets, especially in 2013, 4 years
after publication of the guidance on readability. We considered
4 years to be sufficient time for manufacturers and marketing
authorities to have applied the recommendations in the
guidelines. We also wanted to analyze a potential link between
readability and length. Moreover, the possible influence of some
categorical variables on readability and length was also studied.
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Methods
Type of Study and Inclusion/Exclusion Criteria
We designed and performed an analytical longitudinal study.
The study sample consisted of biological medicine package
leaflets that were authorized by the EMA by January 2007 and
continued to be authorized in December 2013. Of these, one
medicine per active substance was chosen.
The following types of medicines were excluded from the study
so as not to introduce bias into the results: vaccines because
they are used as a prophylactic measure and, moreover, most
are administered by physicians to pediatric patients leading to
reduced importance of package leaflets; insulin products because
diabetic patients usually know their illness and medicines very
well and package leaflet readability is secondary; and botulinum
toxin because it was the only biological medicine at the time of
the study that contained a toxin as an active substance.
Data Collection
The package leaflets were downloaded from the EMA website
[31] at three different times: January 2007, July 2010, and
August 2013. The same pharmaceutical form was chosen in all
three years for each medicine.
Sample Characteristics
As in our previous study [30], the sample of package leaflets
(n=36) was divided into five groups depending on the source
of the drug [32]: monoclonal antibody (mAb) products,
cytokines, therapeutic enzymes, recombinant blood-related
products, and recombinant hormones (see Multimedia Appendix
1).
Five of the six sections according to the EMA package leaflet
model/template [33] were evaluated: (1) what X is and what it
is used for, (2) what you need to know before you take (or use)
X, (3) how to take (or use) X, (4) possible side effects, and (5)
how to store X. The section (6) “contents of the pack and other
information” was excluded because it is considered by patients
less important than the other sections [22] and its content was
highly similar for all the package leaflets. The “annex” section,
which provides information about instructions for use, was also
evaluated in the package leaflets where it appeared (10 leaflets
in 2007, 11 in 2010, and 12 in 2013).
The evaluated sections of the package leaflets were copied as
plain text into individual Microsoft Word 2007 files. Before
calculating quantitative variables, the following modifications
were made:
1. Titles, subtitles, citations, tables, graphs, images, references,
header tables, figure captions, and the brand name of the
medicines were deleted.
2. All abbreviations, unit and magnitude symbols, numbers,
and acronyms were replaced by their full version because
when applying the readability formulas these must be treated
as if read aloud [34].
3. Bullets (eg, dashes, numbers, asterisks) were deleted.
4. Compound words and numbers were considered as a single
word.
Quantitative Variables: Readability Indexes and
Length
The quantitative variables calculated for the package leaflets
were the length (number of words) and three readability indexes:
SMOG grade [34], Flesch-Kincaid grade level [35], and
Szigriszt’s perspicuity index [36].
The readability indexes were chosen taking into account the
following criteria:
1. SMOG grade and Flesch-Kincaid grade level are commonly
used in recently published health care literature and they
have been validated by different methods [37]. This can
make it useful to compare the results obtained with the two
formulas.
2. SMOG grade is recommended for use in health-related
written materials [1,37,38] because it is the only formula
with 100% expected comprehension and is based on more
recent criteria for determining reading grade level. For this
reason, SMOG grade values are usually higher than
Flesch-Kincaid grade level values when both formulas are
applied to the same text [37].
3. The qualitative interpretation of Szigriszt’s perspicuity
index was designed to assess the readability of written
materials in Spanish, which is the language of the package
leaflets analyzed in this study.
The SMOG grade formula has as a variable the number of words
with three or more syllables, whereas the Flesch-Kincaid grade
level and Szigriszt’s perspicuity index use the number of words
per sentence and the number of syllables per word. SMOG grade
was calculated manually following the author’s instructions,
Flesch-Kincaid grade level was calculated using Microsoft Word
2007 software, and Szigriszt’s perspicuity index was calculated
following the author’s instructions (before applying this formula,
both the number of words and the number of sentences were
obtained using Microsoft Word 2007 software and the number
of syllables per word was obtained from previously calculated
Flesch-Kincaid grade level values).
SMOG grade and Flesch-Kincaid grade level indicate reading
grade level (according to the number of years of schooling
required after the age of 6 years to understand the text). Thus,
sixth-grade level is equivalent to age 11 to 12 years, seventh
grade level is equivalent to age 12 to 13, and so on. However,
Szigriszt’s perspicuity index has seven qualitative ranges that
relate the score obtained and the quality of the text: very easy
(85-100), easy (75-85), rather easy (65-75), standard (50-65),
rather difficult (35-50), difficult (15-35), and very difficult
(0-15) [36]. As the Szigriszt’s perspicuity index score increases,
the ease of reading the text also increases. Therefore, the
readability is directly proportional to Szigriszt’s perspicuity
index and inversely proportional to SMOG grade and
Flesch-Kincaid grade level.
The length (numbers of words) of the texts was the fourth
variable obtained from the package leaflets because more words
on package leaflets can decrease the capacity to find certain
information and decrease motivation to read the package leaflet
and confidence in using the medicine correctly after reading it
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[39]. The length was obtained using Microsoft Word 2007
software.
To obtain these variables, the whole text was evaluated in this
study to avoid bias that could be introduced in the choice of
samples.
Categorical Variables
The influence of some categorical variables on readability and
length was studied. These variables were:
1. Year of downloading the package leaflet (three groups):
2007 (n=36), 2010 (n=36), and 2013 (n=36).
2. Section of package leaflet (six groups): (1) what X is and
what it is used for (n=36), (2) what you need to know before
you take (or use) X (n=36), (3) how to take (or use) X
(n=36), (4) possible side effects (n=36), (5) how to store X
(n=36), and annex (n=10 in 2007, n=11 in 2010, n=12 in
2013).
3. Group of medicine according to its source (five groups):
mAb products (n=6), cytokines (n=11), therapeutic enzymes
(n=4), recombinant blood-related products (n=9), and
recombinant hormones (n=6).
4. Date of first authorization of medicine (two groups):
1995-1999 (n=16) and 2000-2002 (n=20).
5. Marketing authorization holder with the real names replaced
by letters (five groups in 2007 and four groups in both 2010
and 2013): A (n=3; only in 2007), B (n=3), C (n=5 in 2007,
n=4 in both 2010 and 2013), D (n=3), and E (n=3). For this
variable, we only considered laboratories with at least three
authorized medicines.
For the second variable (section of package leaflet), the values
per section were taken into account; for the rest of the variables,
the mean of each readability index per package leaflet and the
total length of each package leaflet were considered to have a
single value per package leaflet.
Statistical Analysis
Statistical calculations and box plots were performed using
Deducer (version R 2.15.0) and R-Commander (version R 3.1.0).
The test of normality used in all the comparative studies was
the Shapiro-Wilk test. Taking into account the normality results,
the following statistical tests were used to examine the
relationship between quantitative and categorical variables: (1)
repeated-measures analysis of variance and the Friedman test
to compare different groups of each quantitative variable
according to package leaflet download date; (2) the
Kruskal-Wallis test to compare different groups of quantitative
variables according to package leaflet section, source of
biological medicine, and marketing authorization holder; and
(3) the Mann-Whitney U test, to compare different groups of
quantitative variables according to date of first authorization of
the medicine. Furthermore, the degree of correlation between
the readability indexes and length was estimated via the
coefficient of determination. A P value less than .05 was
considered significant in all the hypothesis tests.
Nonstatistical calculations and the other graphs (both line graphs
and scatterplots) were generated using Microsoft Excel 2007
software.
Results
Effect of Package Leaflet Year on Readability and
Length
Table 1 shows readability (mean values for package leaflet) and
length results for package leaflet and year studied.
All the SMOG grade and Flesch-Kincaid grade level values
exceeded the recommended readability levels for health-related
written materials (all SMOG grade and Flesch-Kincaid grade
level values were much higher than 6). In addition, all the
Szigriszt’s perspicuity index values were less than 75; that is,
no package leaflet was easy to understand according to this
scale. The respective statistical analysis of the results in Table
1 is presented in Table 2.
No statistically significant differences were found in the
readability values between the three years (P=.40 in SMOG
grade, P=.22 in Flesch-Kincaid grade level, P=.20 in Szigriszt
perspicuity index), but differences emerged in terms of the
length (P=.002), with the length of the package leaflets
increasing over the 6-year period (Figure 1).
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Table 1. Mean values of the three readability indexes and total length for package leaflet (n=36) and year studied.
LengthSzigriszt’s perspicuity index,
mean (SD)
Flesch-Kincaid grade level,
mean (SD)
SMOG grade, mean (SD)Medicine
201320102007201320102007201320102007201320102007
94090790560.2
(12.6)
58.9
(13.5)
58.4
(12.3)
16.0
(3.6)
16.3
(4.0)
16.4
(3.8)
16.6
(3.5)
16.6
(3.5)
16.6
(3.5)
Agalsidase alfa
113185198651.6
(19.3)
50.5
(21.7)
45.4
(11.6)
18.2
(5.6)
18.5
(6.2)
19.5
(3.6)
18.4
(4.8)
18.0
(5.1)
18.4
(3.1)
Agalsidase beta
15841429134967.3
(7.9)
68.1
(8.1)
68.4
(8.0)
13.6
(1.8)
13.4
(1.8)
13.3
(1.9)
15.2
(1.5)
14.8
(1.7)
14.8
(1.7)
Anakinra
97094997558.0
(20.6)
58.5
(19.7)
56.3
(13.5)
16.7
(5.6)
16.5
(5.3)
16.6
(3.8)
17.2
(4.7)
17.2
(4.7)
17.0
(3.6)
Basiliximab
17051217121752.9
(15.6)
56.0
(12.1)
56.0
(12.1)
17.4
(3.6)
16.3
(2.8)
16.3
(2.8)
17.6
(2.6)
16.8
(1.9)
16.8
(1.9)
Choriogonadotropin al-
fa
23242125232659.9
(10.4)
62.1
(10.4)
60.8
(8.9)
15.5
(2.5)
15.0
(2.4)
15.4
(2.3)
16.5
(1.4)
16.2
(1.3)
16.3
(1.8)
Darbepoetin alfa
11671167125355.9
(11.9)
55.9
(11.9)
60.9
(6.7)
16.8
(3.2)
16.8
(3.2)
15.2
(1.6)
17.6
(2.7)
17.6
(2.7)
16.2
(1.3)
Desirudin
25792529258759.8
(10.5)
60.0
(10.5)
56.6
(10.4)
15.6
(2.6)
15.5
(2.6)
16.2
(2.7)
16.4
(1.7)
16.4
(2.7)
16.6
(2.1)
Epoetin beta
14311426115862.7
(6.7)
62.1
(7.1)
63.7
(8.2)
15.4
(2.2)
15.5
(2.3)
14.5
(2.1)
16.2
(1.8)
16.2
(1.8)
15.2
(1.8)
Eptacog alfa (activated)
10571608143259.0
(6.0)
53.7
(15.5)
52.8
(17.4)
16.1
(1.8)
18.1
(5.1)
18.1
(5.4)
16.8
(1.6)
18.6
(3.5)
18.6
(3.9)
Eptotermin alfa
45553973310958.6
(11.4)
58.6
(12.1)
58.3
(13.7)
16.9
(3.4)
16.5
(3.3)
16.5
(3.8)
18.2
(2.9)
17.5
(2.7)
17.2
(2.8)
Etanercept
32782561256054.2
(15.4)
51.8
(12.5)
51.8
(12.5)
17.2
(3.8)
17.6
(3.3)
17.6
(3.3)
17.5
(3.1)
17.8
(2.6)
17.8
(2.6)
Follitropin alfa
18741874173757.1
(9.3)
57.2
(9.3)
57.4
(7.3)
16.2
(2.3)
16.2
(2.3)
16.0
(1.9)
16.8
(2.2)
16.8
(2.2)
16.6
(1.9)
Human coagulation
factor IX
17681760176155.5
(12.3)
55.4
(12.1)
55.0
(12.0)
17.0
(3.5)
17.0
(3.5)
17.0
(3.4)
17.8
(3.2)
17.6
(2.9)
17.6
(2.9)
Human protein C
11191062115551.9
(13.9)
51.8
(13.7)
50.4
(8.3)
17.9
(4.1)
17.9
(4.1)
18.0
(2.2)
18.2
(3.7)
18.0
(3.5)
18.2
(2.2)
Imiglucerase
31342701228954.1
(20.1)
55.2
(18.7)
48.4
(12.0)
17.4
(6.1)
17.1
(5.6)
18.3
(3.2)
17.8
(5.3)
17.6
(4.8)
17.8
(2.9)
Infliximab
41464006383357.2
(14.4)
57.5
(14.5)
57.7
(13.9)
16.7
(3.8)
16.6
(3.9)
16.6
(3.7)
17.5
(3.1)
17.8
(3.3)
17.7
(3.4)
Interferon alfa-2b
26302591264064.6
(9.1)
64.7
(9.3)
55.4
(10.8)
14.1
(2.2)
14.1
(2.2)
16.8
(2.8)
15.3
(1.5)
15.5
(1.8)
17.6
(2.5)
Interferon beta-1a
54505463486855.8
(14.3)
55.8
(14.1)
55.6
(9.8)
16.9
(4.0)
17.0
(4.0)
16.8
(2.7)
17.7
(3.1)
17.7
(3.1)
17.3
(2.7)
Interferon beta-1b
23462110179454.0
(11.5)
53.5
(13.3)
54.7
(12.4)
17.1
(3.2)
17.3
(3.6)
17.1
(3.4)
17.8
(3.0)
17.8
(2.9)
17.8
(2.9)
Lutropin alfa
21642169160455.5
(8.7)
57.0
(8.1)
54.1
(13.6)
16.9
(2.2)
16.5
(2.0)
17.2
(3.7)
18.2
(1.9)
17.6
(1.3)
18.0
(3.5)
Moroctocog alfa
24322743249058.3
(10.4)
60.5
(10.5)
58.1
(8.0)
16.2
(2.7)
15.7
(2.7)
16.2
(1.8)
17.2
(1.9)
16.8
(1.6)
17.0
(1.4)
Nonacog alfa
22492403202954.8
(7.2)
53.3
(10.4)
52.9
(8.6)
16.8
(2.0)
17.1
(2.7)
17.3
(2.6)
17.4
(2.3)
17.4
(2.3)
17.6
(2.9)
Octocog alfa
53452654859.4
(18.2)
59.3
(18.2)
61.0
(11.8)
16.0
(4.3)
15.9
(4.2)
15.3
(2.7)
16.6
(3.3)
16.6
(3.3)
15.6
(2.5)
Palivizumab
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LengthSzigriszt’s perspicuity index,
mean (SD)
Flesch-Kincaid grade level,
mean (SD)
SMOG grade, mean (SD)Medicine
201320102007201320102007201320102007201320102007
15211623153266.1
(9.0)
65.3
(9.7)
65.4
(9.8)
14.3
(2.7)
14.7
(3.0)
14.3
(2.4)
15.7
(2.3)
16.2
(2.6)
15.5
(1.6)
Pegfilgrastim
41513545300563.8
(11.7)
64.4
(12.3)
60.5
(21.2)
14.8
(2.6)
14.5
(2.5)
16.1
(6.5)
16.2
(2.0)
15.8
(1.6)
17.3
(5.4)
Peginterferon alfa-2a
57524976382152.1
(22.2)
52.6
(18.5)
53.8
(16.2)
18.6
(7.3)
18.1
(6.9)
17.5
(5.0)
18.7
(5.8)
18.5
(5.0)
17.7
(4.5)
Peginterferon alfa-2b
74571476652.1
(16.1)
53.3
(15.8)
57.4
(14.0)
17.7
(4.1)
17.3
(4.1)
15.7
(3.2)
18.0
(3.5)
17.8
(3.4)
16.2
(1.9)
Rasburicase
19051905184760.4
(9.9)
60.4
(9.9)
60.4
(9.9)
15.9
(2.6)
15.9
(2.6)
15.9
(2.6)
16.8
(2.5)
16.8
(2.5)
16.8
(2.5)
Reteplase
27022109150557.7
(17.7)
59.0
(17.3)
64.0
(10.8)
17.1
(5.6)
16.6
(5.3)
15.0
(3.0)
18.0
(4.8)
17.4
(4.5)
16.2
(2.9)
Rituximab
43884043404153.4
(17.2)
54.9
(15.1)
54.9
(15.3)
17.4
(4.7)
16.7
(3.6)
16.7
(3.6)
17.5
(3.8)
17.0
(2.9)
17.0
(2.9)
Somatropin
96295580051.6
(11.6)
51.4
(10.2)
45.9
(12.2)
17.1
(3.0)
17.2
(2.5)
17.9
(2.2)
16.6
(3.2)
16.6
(2.5)
16.2
(3.3)
Sulesomab
14561433216852.7
(14.5)
56.9
(18.0)
47.6
(9.7)
18.1
(4.3)
16.9
(4.1)
19.4
(2.9)
18.6
(3.8)
17.8
(3.6)
19.2
(2.5)
Tasonermin
127089087854.6
(10.3)
51.9
(14.3)
51.4
(12.4)
17.0
(2.1)
17.6
(3.4)
17.7
(3.0)
17.4
(1.8)
18.0
(3.2)
17.8
(2.8)
Tenecteplase
12861240121955.7
(13.3)
56.8
(14.0)
53.2
(16.8)
16.7
(3.4)
16.4
(3.5)
17.4
(4.4)
17.4
(3.0)
17.2
(3.0)
18.0
(3.6)
Thyrotropin alfa
18581699162556.1
(10.5)
58.5
(14.3)
58.7
(13.3)
17.0
(3.3)
16.6
(4.0)
16.5
(3.8)
17.4
(3.2)
17.0
(3.7)
17.0
(3.4)
Trastuzumab
Table 2. Descriptive statistics of the three readability indexes and length by studied year and results of the hypothesis tests.
PRangeMedian95% CIMean (SD)nVariable and year
.40aSMOG grade
14.8-19.217.116.8-17.417.1 (1.0)362007
14.8-18.617.316.9-17.417.1 (0.8)362010
15.2-18.717.416.9-17.517.2 (0.9)362013
.22bFlesch-Kincaid grade level
13.3-19.516.616.2-17.116.6 (1.3)362007
13.4-18.516.616.1-16.916.5 (1.1)362010
13.6-18.616.916.2-16.916.6 (1.1)362013
.20bSzigriszt’s perspicuity index
45.4-68.456.254.4-58.056.2 (5.2)362007
50.5-68.156.955.8-58.857.3 (4.3)362010
51.6-67.356.055.7-58.557.1 (4.2)362013
.002bLength
548-486816811590-22881939 (1031)362007
526-546318171682-25012091 (1210)362010
534-575218661786-26902238 (1335)362013
a Repeated-measures ANOVA.
b Friedman test.
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Figure 1. Evolution of the medians of length of the package leaflets studied.
Effect of Package Leaflet Section on Readability and
Length
Table 3 and Multimedia Appendix 2 describe the readability
indexes and length per package leaflet section in the three years
studied. Statistically significant differences can be observed
between the four variables and the six sections: (1) what X is
and what it is used for, (2) what you need to know before you
take (or use) X, (3) how to take (or use) X, (4) possible side
effects, (5) how to store X, and (6) annex (P<.001).
These results (Table 3, Multimedia Appendix 2) show the
following order of readability of the sections of the package
leaflets (from easiest to understand to most difficult): (1) section
5, (2) annex, (3) section 3, (4) section 2, (5) section 1, and (6)
section 4. According to the Szigriszt’s perspicuity index medians
(Table 3) and the scale of perspicuity level, section 4 was rather
difficult, section 1 was standard in 2007 and rather difficult in
2010 and 2013, sections 2 and 3 were standard, and section 5
and the annex were rather easy. Thus, sections 1 and 4 were
rather difficult to understand in 2010 and 2013, and the
readability of section 4 (the most difficult section) decreased
during the period studied (Figure 2).
From the median length (Table 3) of the sections of the package
leaflets, the following order was determined from longest to
shortest: (1) annex, (2) section 2, (3) section 3, (4) section 4,
(5) section 1, and (6) section 5. Section 3 decreased in length
during the study years, whereas section 2 increased (Figure 2).
J Med Internet Res 2016 | vol. 18 | iss. 5 | e100 | p.7http://www.jmir.org/2016/5/e100/
(page number not for citation purposes)
Piñero-López et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Table 3. Descriptive statistics of the three readability indexes and length by package leaflet section and year studied.
P aRangeMedian95% CIMean (SD)nVariable, year, and section
SMOG grade
<.0012007
15-2418.017.7-19.118.4 (2.1)361. What X is and what it is used for
14-1917.016.8-17.617.2 (1.3)362. What you need to know before you take (or
use) X
14-2116.015.8-16.716.3 (1.4)363. How to take (or use) X
15-2820.019.5-21.220.3 (2.6)364. Possible side effects
11-1614.013.3-14.113.7 (1.2)365. How to store X
14-1615.014.5-15.515.0 (0.7)106. Annex
<.0012010
15-2319.017.9-19.118.5 (1.8)361. What X is and what it is used for
14-2017.016.8-17.617.2 (1.3)362. What you need to know before you take (or
use) X
14-2016.015.7-16.516.1 (1.2)363. How to take (or use) X
15-2820.519.7-21.720.7 (2.8)364. Possible side effects
11-1614.013.4-14.113.7 (1.0)365. How to store X
14-1615.014.4-15.414.9 (0.7)116. Annex
<.0012013
15-2318.517.9-19.218.6 (1.9)361. What X is and what it is used for
14-2018.016.9-17.817.4 (1.3)362. What you need to know before you take (or
use) X
14-1916.015.8-16.616.2 (1.2)363. How to take (or use) X
16-3021.019.8-22.020.9 (3.3)364. Possible side effects
11-1614.013.5-14.213.9 (1.0)365. How to store X
14-1615.014.5-15.314.9 (0.7)126. Annex
Flesch-Kincaid grade level
<.0012007
14.4-25.618.017.5-19.318.4 (2.7)361. What X is and what it is used for
12.6-18.716.515.9-16.916.4 (1.5)362. What you need to know before you take (or
use) X
12.7-20.915.715.3-16.616.0 (1.9)363. How to take (or use) X
13.8-28.919.319.0-21.020.0 (3.0)364. Possible side effects
10.0-16.712.712.4-13.613.0 (1.7)365. How to store X
11.5-14.912.812.2-13.612.9 (1.0)106. Annex
< .0012010
14.5-24.819.017.8-19.418.6 (2.3)361. What X is and what it is used for
13.3-19.716.616.1-17.116.6 (1.5)362. What you need to know before you take (or
use) X
12.0-19.015.415.0-16.015.5 (1.6)363. How to take (or use) X
13.4-29.620.019.2-21.520.4 (3.4)364. Possible side effects
9.0-16.012.311.7-12.612.2 (1.3)365. How to store X
11.3-14.112.812.2-13.412.8 (0.9)116. Annex
<.0012013
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P aRangeMedian95% CIMean (SD)nVariable, year, and section
14.7-23.218.317.8-19.318.5 (2.2)361. What X is and what it is used for
13.1-20.017.016.2-17.216.7 (1.5)362. What you need to know before you take (or
use) X
12.2-19.515.215.1-16.215.6 (1.7)363. How to take (or use) X
14.9-32.620.119.2-21.820.5 (3.9)364. Possible side effects
9.0-15.212.712.1-12.912.5 (1.2)365. How to store X
11.2-14.113.112.3-13.412.9 (0.9)126. Annex
Szigriszt’s perspicuity index
<.0012007
31.9-64.151.045.8-52.349.0 (9.6)361. What X is and what it is used for
44.7-69.556.654.5-58.456.5 (5.8)362. What you need to know before you take (or
use) X
29.6-71.359.755.1-61.058.0 (8.7)363. How to take (or use) X
20.0-67.045.641.5-47.944.7 (9.5)364. Possible side effects
43.1-82.070.766.6-72.469.5 (8.5)365. How to store X
64.1-78.272.168.9-74.571.7 (3.9)106. Annex
<.0012010
36.4-63.447.245.8-51.348.5 (8.1)361. What X is and what it is used for
43.5-66.156.253.8-57.955.9 (6.0)362. What you need to know before you take (or
use) X
41.0-73.460.757.8-62.560.2 (6.9)363. How to take (or use) X
17.8-68.644.840.9-47.944.4 (10.4)364. Possible side effects
54.3-88.874.371.8-76.274.0 (6.5)365. How to store X
67.4-78.271.269.9-74.372.1 (3.3)116. Annex
<.0012013
28.3-63.450.045.9-51.748.8 (8.6)361. What X is and what it is used for
42.1-68.355.953.9-57.955.9 (5.9)362. What you need to know before you take (or
use) X
39.0-72.660.457.3-62.359.8 (7.5)363. How to take (or use) X
10.7-63.044.840.4-48.044.2 (11.3)364. Possible side effects
58.8-88.872.270.8-74.672.7 (5.6)365. How to store X
67.4-78.070.969.6-73.671.6 (3.2)126. Annex
Length
<.0012007
62-433157140-191166 (75)361. What X is and what it is used for
89-1641502409-628518 (323)362. What you need to know before you take (or
use) X
89-1331422379-617498 (351)363. How to take (or use) X
113-984331320-479399 (236)364. Possible side effects
32-16810088-115102 (39)365. How to store X
481-2114646551-1294922 (519)106. Annex
< .0012010
54-401138131-194163 (93)361. What X is and what it is used for
92-1572478432-660546 (337)362. What you need to know before you take (or
use) X
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P aRangeMedian95% CIMean (SD)nVariable, year, and section
93-1332367362-592477 (339)363. How to take (or use) X
75-1726367368-614491 (364)364. Possible side effects
22-229116101-132116 (46)365. How to store X
479-2114645582-1372977 (588)116. Annex
<.0012013
54-399140136-201168 (96)361. What X is and what it is used for
92-1572530487-750618 (388)362. What you need to know before you take (or
use) X
88-1244350361-582471 (327)363. How to take (or use) X
75-1976342388-677532 (426)364. Possible side effects
22-268127115-149132 (50)365. How to store X
479-2114644584-1310947 (572)126. Annex
a Kruskal-Wallis test.
Figure 2. Evolution of the medians by year of SMOG grade, Flesch-Kincaid grade level, Szigriszt's perspicuity index, and length for the package leaflet
sections. Section 1: what X is and what it is used for; section 2: what you need to know before you take (or use) X; section 3: how to take (or use) X;
section 4: possible side effects; section 5: how to store X; and annex.
Effect of Source of Biological Medicine on Readability
and Length
When comparing readability levels as a function of the source
of the medicine, no statistically significant differences were
observed between the five groups (mAb products, cytokines,
therapeutic enzymes, recombinant blood-related products and
recombinant hormones) of package leaflets (SMOG grade:
P=.44 in 2007, P=.31 in 2010, P=.61 in 2013; Flesch-Kincaid
grade level: P=.46 in 2007, P=.11 in 2010, P=.09 in 2013;
Szigriszt’s perspicuity index: P=.34 in 2007, P=.08 in 2013),
except when considering Szigriszt’s perspicuity index in 2010
(P=.03). However, differences could be observed between the
five groups in the length of the package leaflets in the 3 years
studied (P=.002 in 2007, P=.007 in 2010, P=.009 in 2013).
These differences in length were mainly due to the difference
between therapeutic enzymes and cytokines when applying the
Bonferroni posttest for multiple comparisons (Table 4).
Cytokines had the longest package leaflets: a median of 2640
words (range 1349-4868) in 2007, 2591 words (range
1429-5463) in 2010, and 2630 (range 1456-5752) in 2013; and
therapeutic enzymes had the shortest: a median of 946 words
(range 766-1155) in 2007, 879 words (range 714-1062) in 2010,
and 1030 (range 745-1131) in 2013.
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Table 4. P values obtained by applying the Bonferroni posttest for multiple comparisons of package leaflet length.
P valueYear and type of medicine
Recombinant blood-related
products
Therapeutic en-
zymes
CytokinesmAb products
2007
———.048Cytokines
——.02.99Therapeutic enzymes
—.20.06.99Recombinant blood-related products
.99.10.99.99Recombinant hormones
2010
———.37Cytokines
——.02.99Therapeutic enzymes
—.11.47.99Recombinant blood-related products
.99.10.99.99Recombinant hormones
2013
———.78Cytokines
——.02.99Therapeutic enzymes
—.03.20.99Recombinant blood-related products
.99.38.99.99Recombinant hormones
Effect of Date of First Authorization on Readability
and Length
No statistically significant differences were observed in
readability levels and length between the leaflets of medicines
authorized in 1995-1999 (n=16) and those authorized in
2000-2002 (n=20) as a function of the year of first authorization
of the biological medicine (SMOG grade: P=.81 in 2007, P=.79
in 2010, P=.99 in 2013; Flesch-Kincaid grade level: P=.79 in
2007, P=.81 in 2010, P=.94 in 2013; Szigriszt’s perspicuity
index: P=.57 in 2007, P=.78 in 2010, P=.96 in 2013; length:
P=.90 in 2007, P=.95 in 2010, P=.90 in 2013). However,
differences in the descriptive analysis of the data were observed
between the medians of the length of the groups: the medians
of length of the medicines authorized in 1995-1999 were higher
than those of medicines authorized in 2000-2002 in the three
years studied. The medians of length for the medicines
authorized in 1995-1999 were 1726 (range 548-4868) in 2007,
2007 (range 526-5463) in 2010, and 2035 (range 534-5450) in
2013, although those of the medicines authorized in 2000-2002
were 1681 (range 766-4041) in 2007, 1730 (range 714-4976)
in 2010, and 1813 (range 745-5752) in 2013.
Effect of Marketing Authorization Holder on
Readability and Length
Even though differences were found between groups for the
readability indexes in 2007 and for Szigriszt’s perspicuity index
in 2010 and 2013 (SMOG grade: P=.01 in 2007; Flesch-Kincaid
grade level: P=.01 in 2007; Szigriszt’s perspicuity index: P=.01
in 2007, P=.03 in 2010, P=.04 in 2013), these differences not
were observed in the Bonferroni posttest for multiple
comparisons (P>.05). This was probably due to a lack of
statistical power because the samples were considered too small.
For this reason, regarding the comparative study of groups of
package leaflets as a function of marketing authorization holder,
no statistical evidence was available to show the influence of
marketing authorization holder on readability and length.
Relationship Between Quantitative Variables
The results of studying the relationship between the three
readability indexes and length are presented in Table 5.
Table 5. Correlations between the three readability indexes and length.
LengthSzigriszt’s perspicuity indexFlesch-Kincaid grade levelSMOG gradeVariable
P ar 2P ar 2P ar 2P ar 2
<.001.05<.001.81<.001.92——SMOG grade
<.001.03<.001.95————Flesch-Kincaid
grade level
.003.02——————Szigriszt’s per-
spicuity index
a ANOVA.
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Although the P value was significant for all pairs of variables,
taking into account the coefficient of determination, only a linear
correlation between the readability indexes was evident. This
correlation can be observed in the respective scatterplots (Figure
3).
Figure 3. Scatterplots relating SMOG grade, Flesch-Kincaid grade level, Szigriszt's perspicuity index, and length.
Discussion
Principal Findings
The objective of this study was to determine the readability and
length of package leaflets for biological medicines in three
different years. Our results show that none of the package
leaflets evaluated met the recommended readability levels for
health-related written materials. Therefore, the package leaflets
are not in line with European legislation, according to which
they must be clearly legible and understandable [23]. This
finding could negatively affect patient understanding of the
information contained in package leaflets and result in a
reduction of adherence intentions [40,41]. A recent study in
which patient information materials were evaluated in terms of
readability and variety of content found that these materials did
not promote health literacy and were only accessible to a
proportion of higher skilled patients, which could ultimately
increase inequalities in health [42].
Moreover, no improvement in readability was observed over
the 6-year period analyzed. This result was not in line with our
expectations because the European Commission Guideline [24]
recommended the use of words with few syllables and avoidance
of long sentences in 2009. In accordance with this guideline,
the readability of package leaflets should have increased, but
this is not the case.
Furthermore, the number of words in package leaflets increased
between 2007 and 2013, which is also a problem for patients.
This trend has existed in Europe for a number of years [39].
The observed increase in the length of the package leaflets over
the 6-year period studied could be a consequence of prevention
policies of the EMA and the time since first authorization that
may lead to there being more information related to
pharmacovigilance.
When the sections of package leaflets were compared,
differences between them were observed in both readability and
length in all the years studied. The most difficult sections contain
information about therapeutic indications (section 1: what X is
and what it is used for) and side effects of the medicines (section
4: possible side effects). This information is considered very
important by patients [22] because it highlights the importance
of promoting an understanding of the need for medicines and
individual risk for side effects when taking medicines [43], and
allows them to undertake a rational benefit-risk assessment of
their medication [44]. Herber et al [44] stated that “package
leaflets need to convey potential risk information in a language
that is less frightening while retaining the information content
required to make informed decisions about the prescribed
medication.” In contrast, the most understandable section
(section 5: how to store X) is considered less important by
patients [22].
Regarding the length of sections, the shortest section was section
5 (how to store X) and it was also the most understandable. In
contrast, the annex section was the longest section, but it was
more understandable than other sections because it has shorter
sentences and contains fewer technical terms. Moreover, section
4 (possible side effects) was not the longest section, but it was
the least understandable as mentioned previously. This is
because in most package leaflets it contains a long list of
difficult medical words, which can prevent appropriate
interpretation by patients [39].
In relation to the studied correlation between the three readability
indexes and total length, only the readability indexes showed
an acceptable linear relationship, which was not observed
between the readability indexes and length. Thus, we can
conclude that the readability of package leaflets is not associated
with their length. Fitzsimmons et al [1] assessed the readability
of online consumer-oriented Parkinson’s disease information
using the Flesch-Kincaid grade level and SMOG grade formulas.
They found that webpage length was not associated with
readability, suggesting that reading difficulty of websites
evaluated was independent of word count. Nevertheless, it is
J Med Internet Res 2016 | vol. 18 | iss. 5 | e100 | p.12http://www.jmir.org/2016/5/e100/
(page number not for citation purposes)
Piñero-López et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
recommendable to reduce the length of package leaflets to make
them easier to read and to motivate the patient to access and
understand them [1,39]. Indeed, some authors have proposed
an alternative template for European package leaflets [45].
Limitations
Our study has some limitations. First of all, one limitation is
the lack of a test of package leaflets according to target patient
groups. According to Article 59(3) of Directive 2004/27/EC,
package leaflets should reflect the results of user testing to
ensure readability. Methods to assess package leaflets using
patients have been published [24,46,47], but there are also
different studies published in which the results obtained by
applying readability formulas and those using user testing have
been consistent [48]. Thus, before undertaking a user test or
any other form of user consultation [24], the use of formulas
can be considered a first step to predict understandability and
to initially identify readability problems independently of the
type of patient.
A second limitation of this research is the lack of assessment
of other characteristics of package leaflets that also improve
their readability, such as font, figures, design, and layout
[16,24,47,49]. It is important to point out that there are several
indirect instruments that assess these characteristics in
health-related written materials, such as Suitability Assessment
of Materials (SAM) [16] and Patient Education Materials
Assessment Tool (PEMAT) [50].
Lastly, not all biological medicines were considered in this
study. A sample of 36 biological medicines authorized in both
2007 and 2013 was analyzed taking into account the inclusion
and exclusion criteria established. This sample constituted 36
of 61 (approximately 60%) medicines that complied with these
criteria in January 2007 and only 36 of 126 (approximately
30%) in January 2013 [28].
Nevertheless, three readability formulas were used (and one of
them especially for Spanish) to provide an objective measure
of difficulty [11] of reading package leaflets. Moreover, the
criteria for obtaining readability indexes have been explained
in detail, allowing future comparisons with other studies.
Furthermore, to avoid interpretation problems due to a bias in
the selection of text samples, all the information contained in
the package leaflets was used to calculate the quantitative
variables. Finally, this longitudinal study considered adaptation
to EU guidelines over a 6-year period of the same health-related
written materials.
Future Implications and Conclusions
Most studies to date have shown that the materials targeted at
patients are written with readability levels that make it difficult
for the materials to be understood by most people. Package
leaflets are this type of written material; therefore, they are no
exception to what has been confirmed.
We continue to believe that it would be more than reasonable
for applicants and marketing authorization holders, who are
responsible for drawing up the package leaflets according to
the EMA instructions, to be more conscious of the need to
improve the readability of package leaflets together with a
decrease of their length. This would increase the usefulness of
package leaflets and access to the information they contain by
patients.
In the same way, it is advisable for those responsible for drawing
up the package leaflets to measure the readability with some of
the formulas applied here (which we have shown to be highly
correlated), as a method adopted in parallel to direct methods
using patients. In this way, taking the measures as soon as
possible and, depending on the results, package leaflets could
be revised if necessary. Future studies are needed to explain the
reasons why the readability of package leaflets has not improved
over the years considered in this study, even though the EU
legislation and guidelines have changed.
Finally, we suggest an alternative type of written
medicine-related information targeted at patients that covers
their information needs because the current package leaflet in
the EU has proved to be a barrier that has not introduced
significant changes in either its readability or length. The
alternative written material should be more concise (shorter)
than the current package leaflets and it should be written in clear
language that is comprehensible for patients.
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Multimedia Appendix 1
Biological medicines studied (n=36).
[PDF File (Adobe PDF File), 69KB - jmir_v18i5e100_app1.pdf ]
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Multimedia Appendix 2
Descriptive statistics of SMOG grade, Flesch-Kincaid grade level, Szigriszt's perspicuity index, and length for each package
leaflet section and year studied. Section 1: what X is and what it is used for; section 2: what you need to know before you take
(or use) X; section 3: how to take (or use) X; section 4: possible side effects; section 5: how to store X; and annex.
[PDF File (Adobe PDF File), 4MB - jmir_v18i5e100_app2.pdf ]
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